

Smith et al.,

**Role for the Na<sup>+</sup>/K<sup>+</sup> ATPase pump alpha 3 (*ATP1A3*) subunit  
in folding and lamination of the human neocortex**

Richard S. Smith<sup>1</sup>, Marta Florio<sup>2,3</sup>, Shyam K. Akula<sup>1,4</sup>, Jennifer E. Neil<sup>1</sup>, Yidi Wang<sup>1</sup>, R. Sean Hill<sup>1</sup>, Melissa Goldman<sup>2,3</sup>, Christopher D. Mullally<sup>2,3</sup>, Nora Reed<sup>2,3</sup>, Luis Bello-Espinosa<sup>5</sup>, Laura Flores-Sarnat<sup>6</sup>, Fabiola Paoli Monteiro<sup>7</sup>, Casella B. Erasmo<sup>8</sup>, Filippo Pinto e Vairo<sup>9,10</sup>, Eva Morava<sup>10</sup>, A. James Barkovich<sup>11</sup>, Joseph Gonzalez-Heydrich<sup>12</sup>, Catherine A. Brownstein<sup>1</sup>, Steven A. McCarroll<sup>2,3</sup>, Christopher A. Walsh<sup>1</sup>

<sup>1</sup>Division of Genetics and Genomics, Howard Hughes Medical Institute, Broad Institute of MIT and Harvard, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

<sup>2</sup>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA

<sup>3</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA

<sup>4</sup>Harvard-MIT MD/PhD Program; Program in Neuroscience; Harvard Medical School, Boston, MA, 02115, USA

<sup>5</sup>Arnold Palmer Hospital for Children, Orlando, FL, 32806, USA

<sup>6</sup>University of Calgary and Alberta Children's Hospital Research Institute (Owerko Centre), Dept of Paediatrics and Clinical Neurosciences, Calgary, Alberta, Canada

<sup>7</sup>Mendelics Genomic Analysis, CEP 04013-000, São Paulo, SP, Brazil

<sup>8</sup>Children's Institute, Hospital das Clinicas, São Paulo, SP, Brazil

<sup>9</sup>Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA

<sup>10</sup>Department of Clinical Genomics, Mayo Clinic, Rochester, MN, 55905, USA

<sup>11</sup>Benioff Children's Hospital, Departments of Radiology, Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, CA, 94117, USA

<sup>12</sup>Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

\*Correspondence should be addressed to: [Richard.smith@childrens.harvard.edu](mailto:Richard.smith@childrens.harvard.edu) and [christopher.walsh@childrens.harvard.edu](mailto:christopher.walsh@childrens.harvard.edu)

Smith et al.,

45  
46 **ABSTRACT**

47  
48 Osmotic equilibrium and membrane potential in animal cells depend on concentration gradients of  
49 sodium ( $\text{Na}^+$ ) and potassium ( $\text{K}^+$ ) ions across the plasma membrane, a function that is catalyzed  
50 by the Na,K-ATPase alpha subunit. In vertebrates, four paralogous genes, *ATP1A1-4*, encode  
51 distinct alpha subunit isoforms ( $a_1$ - $a_4$ ), three of which ( $a_1$ ,  $a_2$ ,  $a_3$ ) are expressed in the brain, and  
52 two ( $a_1$ ,  $a_3$ ) predominantly in neurons. The  $a_3$  isoform, encoded by *ATP1A3*, is critical to neuronal  
53 physiology, and a growing spectrum of neurological diseases are associated with *ATP1A3*  
54 pathogenic variants, with ages of onset ranging from early childhood to adulthood. Here, we  
55 describe *ATP1A3* variants encoding dysfunctional  $a_3$  subunits in children affected by  
56 polymicrogyria, a developmental malformation of the cerebral cortex characterized by abnormal  
57 folding and laminar organization. To gain cell-biological insights into the spatiotemporal dynamics  
58 of prenatal *ATP1A3* expression, we established a transcriptional atlas of *ATP1A3* expression during  
59 cortical development using mRNA *in situ* hybridization and transcriptomic profiling of ~125,000  
60 individual cells with single-cell RNA sequencing (Drop-Seq) from various areas of the  
61 midgestational human neocortex. We find that fetal expression of *ATP1A3* is restricted to a subset  
62 of excitatory neurons carrying transcriptional signatures of neuronal activity and maturation  
63 characteristic of the developing subplate. Furthermore, by performing Drop-Seq on ~52,000 nuclei  
64 from four different areas of an infant human neocortex, we show that *ATP1A3* expression persists  
65 throughout early postnatal development, not only within excitatory neurons across all cortical  
66 layers, but also and more predominantly in inhibitory neurons, with specific enrichment in fast-  
67 spiking basket cells. In addition, we show that *ATP1A3* expression, both in fetal and postnatal  
68 neurons, tends to be higher in frontal cortical areas than in occipital areas, in a pattern consistent  
69 with the rostro-caudal maturation gradient of the human neocortex. Finally, we discover distinct

Smith et al.,  
70 co-expression patterns linking catalytic  $\alpha$  subunit isoforms (*ATP1A1,2,3*) and auxiliary isoforms  
71 (*ATP1B1,2,3*), suggesting the ATPase pump may form non-redundant, cell-type specific  $\alpha$ - $\beta$   
72 combinations. Together, the importance of the developmental phenotypes and dynamic expression  
73 patterns of *ATP1A3* point to a key role for *a3* in the development and function of human cortex.

74

75 **Keywords**

76 Na,K-ATPase, *ATP1A3*, Cortical Development, Cortical Malformation, Developmental  
77 Channelopathy, DYT12, EIEE, Subplate, Polymicrogyria

78

79

80 **GLOSSARY**

81 - *ATPIA3*: Na<sup>+</sup>,K<sup>+</sup>-ATPase alpha 3 subunit

82 - PMG: Polymicrogyria (an overfolded cerebral cortex)

83 - MCD: Malformation of cortical development

84 - EN: Excitatory neuron

85 - IN: Inhibitory neuron

86 - NPC: Neural progenitor cell

87 - SP: Subplate

88 - Vm: Resting membrane potential

89 - WPC: Weeks post conception

90 - AHC: Alternating hemiplegia of childhood

91 - RDP: Rapid-onset dystonia-parkinsonism

92 - CNS: Central Nervous System

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Smith et al.,

111 **INTRODUCTION**

112

113           Generating a folded, 6-layered cerebral cortex relies on the integration of signals from a  
114 variety of cell types, coordinating schedules of cell proliferation, migration, differentiation, and  
115 maturation. These processes require proper maintenance of ionic gradients and cell membrane  
116 potential ( $V_m$ ) and thus rely on the precise function of ion channels and pumps. Pathogenic  
117 mutations in genes encoding ion channels can cause malformations of cortical development  
118 (MCDs), collectively known as developmental channelopathies (Smith and Walsh, 2020). For  
119 example, pathogenic variants in prenatally expressed genes encoding glutamate (*GRIN2B*, *GRIN1*)  
120 and sodium channels (*SCN3A*) can lead to MCDs (Fry et al., 2018; Platzer et al., 2017; Smith et  
121 al., 2018), at least in part via gain-of-function, cell-autonomous effects in neurons and potentially  
122 other cell types (Smith et al., 2018). These developmental channelopathy variants in glutamate and  
123 sodium channels cause pathogenic increases in cationic flux into cells (Smith and Walsh, 2020),  
124 affecting  $V_m$  in neural progenitor cells and neurons, which has been shown to be sufficient to  
125 disrupt neurogenic and cortical lamination processes in experimental models (Hurni et al., 2017;  
126 Vitali et al., 2018).

127           Neuronal physiology, homeostasis, and signaling depend on the electrogenic activity of the  
128 Na,K-ATPase, an ionic pump powered by ATP hydrolysis which maintains  $Na^+$  and  $K^+$  gradients  
129 across the plasma membrane. The Na,K-ATPase complex contains a large catalytic subunit ( $\alpha$ )  
130 and two auxiliary subunits ( $\beta$ , FXYD) (Holm et al., 2016). In vertebrates, four paralogous genes  
131 (*ATP1A1-4*) encode  $\alpha$  subunits, of which the *ATP1A3* isoform is predominantly expressed in the  
132 brain and is critical to the restitution of electrochemical gradients following neuronal excitation,  
133 among several other physiological functions (Kim et al., 2004; McGrail et al., 1991; Picton et al.,  
134 2017). Pathogenic variants in *ATP1A3* have been increasingly associated with a spectrum of

Smith et al.,  
135 neurological diseases, with phenotypes ranging broadly in age of onset, from the immediate  
136 postnatal period throughout adulthood(Brashear et al., 1993; Smedemark-Margulies et al., 2016),  
137 suggesting different vulnerabilities to *ATPIA3* dysfunction during childhood brain maturation.  
138 These diseases include (in approximate order of onset in childhood development): early infantile  
139 epileptic encephalopathy (EIEE); alternating hemiplegia of childhood (ACH); cerebellar ataxia,  
140 areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS); childhood onset  
141 schizophrenia (COS); and rapid-onset dystonia-parkinsonism (RDP)(Brashear et al., 1993;  
142 Smedemark-Margulies et al., 2016). Variants in *ATPIA3* associated with these postnatal diseases  
143 are generally categorized as heterozygous loss-of-function single nucleotide  
144 variants(Arystarkhova et al., 2019; Holm et al., 2016) which, among other deficits, have been  
145 shown to lead to depolarized Vm, such as in neurons from AHC patients(Simmons et al., 2018).  
146 During development, bioelectric changes can dramatically alter both intrinsic trajectories of  
147 individual cells(Levin et al., 2017) and cortical lamination more broadly(Hurni et al., 2017; Vitali  
148 et al., 2018), suggesting that bioelectric alterations in early brain development could in part  
149 contribute to subsequent *ATPIA3*-related neurological disorders.

150 Here, we present four individuals with novel *de novo ATPIA3* variants resulting in  
151 polymicrogyria (PMG, the most common MCD(Jansen et al., 2016)), epilepsy, and global  
152 developmental delay, and consider a previously described individual case report of AHC with  
153 polymicrogyria(Gurrieri et al., 2016). The *ATPIA3* variants we observed associated with PMG  
154 clustered in transmembrane regions 7 to 8 of the  $\alpha 3$  protein. Using mRNA *in situ* analysis and  
155 single-cell RNA sequencing (Drop-Seq) in the human fetal cortex at mid-gestation, we show that  
156 *ATPIA3* is restricted to a subset of deep-layer neurons located in the subplate. Moreover, using  
157 Drop-Seq in the human infant cortex, we show that postnatal expression of *ATPIA3* at this stage

Smith et al.,  
158 of development extends not only to all excitatory neuron subtypes (with cortical layer biases), but  
159 mostly predominates within cortical interneurons. The infant cortex also displays a rostral-to-  
160 caudal *ATPIA3* gradient, with highest expression levels in the prefrontal cortex. Last, within  
161 individual cells, variable levels of ATPase  $\alpha$  and  $\beta$  subunit isoforms offers differential vulnerability  
162 between excitatory and inhibitory neurons, and may provide a partial explanation for the broad  
163 phenotypic range associated with *ATPIA3* mutations.

Smith et al.,

164 **RESULTS**

165

166 **Individuals with *ATPIA3* variants display cortical malformation phenotypes**

167

168 Magnetic resonance imaging (MRI) of four unrelated individuals with *de novo ATPIA3*

169 variants revealed a range of PMG severity, from extensive bilateral frontoparietal PMG to

170 unilateral PMG (**Figure 1A**). Detailed descriptions of each case are included in supplemental text.

171

172 *Case A: Bilateral Frontoparietal PMG (p.Arg901Met)*

173 Case A, a female child of nonconsanguineous parents from Portugal, was born at full term

174 and had a short postnatal hospital stay for respiratory distress and jaundice. Brain MRIs performed

175 at 5 months and at 9 years of age revealed extensive bilateral perisylvian polymicrogyria involving

176 the lateral temporal lobes, insulae, and posterior half of frontal and parietal lobes (**Figure 1A**).

177 The posterior part of frontal and temporal cortex appears abnormally thick, with somewhat shallow

178 sulci, giving a pachygyric appearance (bilateral and fairly symmetrical, but with a mild left to right

179 predominance). The most anterior aspects of the frontal and parietal lobes, as well as the medial

180 and inferior cerebral cortex, were spared. At 9 years she developed seizures, manifesting as focal

181 impaired awareness, and was treated with oxcarbazepine. She was developmentally and

182 cognitively delayed, able to sit alone and walk with a walker, point and make some signs but had

183 no speech, and could hold a pencil but not write. Asymmetric spastic quadriparesis (left more

184 significant than right) with hypertonia and athetoid movements of the hands and fingers were noted

185 on examination, as were a high palate, thin upper lip and smooth philtrum. Her head circumference

186 at 9 years was 51 cm (-0.73 standard deviations, SD), and she exhibited drooling and had feeding

187 difficulties. Trio whole exome sequencing (WES) revealed a *de novo ATPIA3* variant, c.2702G>T

188 (p.Arg901Met), absent in both parents (**Figure 1 & S1**).



Smith et al.,

189 *Case B: Extensive Bilateral PMG (c.2921+1G>A)*

190 Case B, a male child of nonconsanguineous parents from the Philippines, was born at 38  
191 weeks' gestation. His head circumference at birth was 34 cm (-0.83 SD) and he developed seizures  
192 12 hours after delivery. Brain MRI at 6 weeks revealed extensive bilateral polymicrogyria, and  
193 small, cyst-like areas were noted within the hippocampal heads and bodies. Video EEGs confirmed  
194 a severe epileptic encephalopathy resistant to essentially all antiepileptic drugs. EEGs at 2 months  
195 of age showed abundant electroclinical and electrographic seizures beginning predominantly from  
196 the right parasagittal region but also from the left and bilateral parasagittal regions. Visual and  
197 auditory evoked potential studies were normal at 4 and 5 months of age respectively. Evaluation  
198 at 14 months revealed microcephaly, with a head circumference of 41.5cm (-4.63 SD), severe  
199 global developmental delay (never rolled over, sat up, or talked), intermittent nystagmus,  
200 significant axial and appendicular hypotonia, and hyporeflexia. Trio WES revealed a *de novo*  
201 *ATPIA3* variant, c.2921+1G>A, disrupting a conserved splice site, absent in both parents (**Figure**  
202 **1A & S1**).

203

204 *Case C: Unilateral PMG (p.Leu924Pro)*

205 Case C, a male child of nonconsanguineous parents from Brazil, was born at 38 weeks'  
206 gestation by Cesarean section for fetal distress. He was hypotonic and noted to have a left clubfoot  
207 at birth and was admitted to neonatal intensive care when episodes of upward rolling of the eyes  
208 were noted on the first day of life. MRI revealed extensive cortical malformation of the right  
209 hemisphere with polymicrogyria comprising the frontal, parietal, and temporal right lobes and the  
210 insula, and a small focus of signal abnormality in the periventricular white matter, compatible with  
211 recent ischemic injury. EEG revealed the presence of electroclinical seizures and his neurological

Smith et al.,

212 exam at the time disclosed episodic dystonic posturing of the upper left extremity alternating with  
213 excessive movements of closing his left hand with thumb adduction. He was discharged on  
214 phenobarbital and levetiracetam. Upon neurological exam at 8 months of age, he had a head  
215 circumference of 42.5 cm (-1.75 SD), very poor eye contact, global hypotonia with present  
216 reflexes, absent head support, absence of rolling and of object gripping, and presence of babbling  
217 sounds. Trio WES revealed a *de novo* *ATPIA3* variant, c.2771T>C (p.Leu924Pro), absent in both  
218 parents (**Figure 1 & S1**).

219

220 *Case D: Extensive multifocal PMG (p.Gln851Arg)*

221 Case D, a male child of nonconsanguineous parents of European descent from the United  
222 States, was born at 41 weeks by emergency Cesarean section; the pregnancy was complicated by  
223 fetal hydronephrosis. He developed electroclinical seizures and a neonatal encephalopathy  
224 requiring cooling and was discharged after 1 month. MRI soon after birth showed multifocal PMG  
225 involving both cerebral hemispheres, right greater than left, with the right hemisphere smaller than  
226 the left (**Figure 1A**). At 4 months of age he was admitted for congenital hip dysplasia surgery and  
227 noted to have frequent breath holding spells that worsened after the surgery. His varied seizure  
228 phenomenology included nystagmus, chin quivering, and hand shaking, which continue  
229 intermittently even through phenobarbital, levetiracetam, and oxcarbazepine combination therapy.  
230 At 15 and 30 months of age, head circumference was 42.7 cm (-3.5 SD) and 44.2 cm (-3.3 SD),  
231 respectively. Physical exam at 18 months demonstrated spastic hemiparesis involving primarily  
232 left arm, but including ipsilateral face, and central hypotonia. Other symptoms include feeding  
233 difficulties and persistent constipation. WES revealed a *de novo* *ATPIA3* variant, c.2552A>G  
234 (p.Gln851Arg), absent in mother (father was not available for testing).

Smith et al.,

235

236 **PMG-associated *ATPIA3* mutations are predicted to disrupt function**

237 *ATPIA3* encodes the P-type Na,K-ATPase  $\alpha 3$  subunit (NM\_152296), an integral  
238 membrane protein that relies on ATP hydrolysis to transport ions ( $\text{Na}^+$  and  $\text{K}^+$ ) via 10 membrane-  
239 inserted helices (TM1-TM10). This ATPase is functionally supported by the  $\beta$  and FXYD  
240 subunits(Holm et al., 2016). *ATPIA3* has several conserved domains across  $\alpha$  isoform paralogs  
241 ( $\alpha 1-4$ ) and orthologous genes(Clausen et al., 2017), and is a highly constrained gene, with many  
242 fewer missense and loss of function variants seen in the general population than predicted  
243 (gnomAD Z score of 6.33 and pLI score of 1.0 respectively). Taken together with *ATPIA3*'s  
244 known disease association with AHC, RDP, IEE, and CAPOS(Brashear et al., 1993), this suggest  
245 the newly identified variants in *ATPIA3* are likely damaging (**Table S1**).

246 PMG-associated *ATPIA3* variants (p.Gln851Arg, p.Leu888Pro, p.Arg901Met,  
247 p.Leu924Pro, and c.2921+1G>A), occur at sites that are highly conserved among the  $\alpha$  subunit  
248 paralogs (*ATPIA1* – *ATPIA4*) and invariant in other vertebrate *ATPIA3* orthologs (**Figures S1B**).  
249 *In silico* pathogenicity predictions for p.Gln851Arg, p.Arg901Met, p.Leu924Pro, and  
250 c.2921+1G>A suggest these variants are likely deleterious and disease causing (**Table S1**). Two  
251 amino acid substitutions reported here, Leu924Pro and Gln851Arg, were previously associated  
252 with EIEE and AHC without MCD(Arystarkhova et al., 2019; Masoud et al., 2017), further  
253 supporting the wide spectrum of *ATPIA3* phenotypes resulting from single amino acid variants  
254 (**Table S3**). Leu924Pro pathogenicity was also demonstrated to affect ATPase trafficking to the  
255 plasma membrane, categorized functionally as loss-of-function (LOF), or viewed as a toxic gain-  
256 of-function effect.(Arystarkhova et al., 2019) Together, the conservation of nucleotides and  
257 absence of variants in population databases suggests these PMG *ATPIA3* alleles are likely

Smith et al.,

258 pathogenic.

259 PMG-associated missense *ATPIA3* variants (p.Gln851Arg, p.Leu888Pro, p.Arg901Met,  
260 p.Leu924Pro) cluster within TM7 to TM8 segments. The *de novo* *ATPIA3* variant in Case A,  
261 NM\_152296.4:c.2702G>T, p.Arg901Met (R901M), affects an arginine in the extracellular loop  
262 connecting transmembrane domains 7 and 8 (TM7-TM8; **Figures 2A, S1A**), in the same segment  
263 as a previously described variant (p.Leu888Pro) occurring in an AHC individual with  
264 PMG(Gurrieri et al., 2016). Arg901 and Leu888 amino acids are in close proximity to Glu899,  
265 Gln904, and Gln905, which interact with the Na,K-ATPase  $\beta$  subunit(Shinoda et al., 2009) (**Figure**  
266 **2B**). Case C possesses a *de novo* *ATPIA3* variant, NM\_152296.4:c.2771T>C, (p.Leu924Pro),  
267 altering an amino acid in the TM7 helix just upstream of the loop (**Figures 2B**). Case D possesses  
268 a *de novo* *ATPIA3* variant, NM\_152296.4:c.2552A>G, p.Gln851Arg, altering an amino acid in  
269 TM7 (**Figure 2B**). Although the clustering of these missense variants may be seen as suggesting  
270 disruption of specific protein-protein interactions, on the other hand, the *de novo* *ATPIA3* variant  
271 in Case B, NM\_152296.4:c.2921+1G>A, abolishes the essential splice donor site of exon 21  
272 (**Figure S1**), and similar *ATPIA3* splice site variants are known to cause AHC(Viollet et al., 2015).  
273 Therefore, the PMG-associated variants may all represent LOF, with the more severe phenotype  
274 reflecting more complete LOF than for some other *ATPIA3*-associated conditions.

### 275 *ATPIA3* mRNA expression in the human fetal neocortex

277 To investigate the transcriptional trajectory of *ATPIA3* during human brain development  
278 underlying the prenatal phenotypes described in this study, we first contrasted the temporal  
279 expression patterns of *ATPIA1-3* across brain regions, mining bulk neocortical transcriptome data  
280 from the Allen Brain Atlas(Jones et al., 2009), ranging from 12 weeks post conception (wpc) to  
281 adulthood (40 year-old) (**Figure 3**). We find that prenatal expression of *ATPIA3* is higher than

Smith et al.,  
282 that of its paralogs, and that *ATPIA3* persists postnatally (**Figure 3B**). To gain further insights into  
283 the cell-biological mechanisms underlying the developmental cortical phenotypes described in this  
284 study, we characterized the patterns of *ATPIA3* expression in the midgestational fetal human  
285 neocortex (wpc 19-21). This developmental age offers a uniquely informative window into  
286 corticogenesis as many and diverse biological processes – including neurogenesis, neuronal  
287 migration and differentiation, and cortical folding – co-occur at this age. At this stage, early-born  
288 excitatory neurons (ENs) have settled and started to differentiate within the innermost strata of the  
289 cortical plate (CP) (prospective layers 6a-5), while later-born ENs progressively migrate past their  
290 predecessors to occupy the most superficial aspect of the CP (prospective layers 4-2)(Miller et al.,  
291 2014). A large fraction of upper-layer ENs are still being generated in the germinal zones, while  
292 others – en route to the CP – are withheld within the subplate (SP), a transient developmental layer  
293 crucial for corticogenesis, where ENs are primed by thalamic input and form transient synaptic  
294 connections with one another and with resident SP neurons (prospective layer 6b)(Luhmann et al.,  
295 2018).

296 To investigate *ATPIA3* expression in its tissue context, we performed RNA *in situ*  
297 hybridization (ISH) in a coronal cross-section of fetal neocortex at 19 wpc. *ATPIA3* mRNA was  
298 virtually undetectable in the germinal zones (ventricular and subventricular zone, VZ and SVZ)  
299 but abundant in postmitotic neuronal layers, with highest expression in the inner CP and SP  
300 (**Figure 3C & D**). Multiplexed fluorescent ISH analysis of *ATPIA3* with markers of two  
301 populations of cortical neural progenitor cells, radial glia and intermediate progenitor cells,  
302 confirmed *ATPIA3* is not expressed in these dividing cells or their immediate progeny in either the  
303 VZ or the SVZ (**Figure 3C**). In addition, since *ATPIA3*-associated diseases display a range of  
304 cerebellar deficits(Brashear et al., 1993; Sweadner et al., 2016; Uchitel et al., 2019), we also

Smith et al.,  
305 evaluated *ATPIA3* expression in the fetal cerebellum (19 wpc), demonstrating an exclusive  
306 enrichment of *ATPIA3* within the Purkinje cell layer (**Figure 3E**).

307

308 **Fetal neocortex single cell analysis demonstrates robust *ATPIA3* enrichment to resident**  
309 **subplate neurons and rostral neocortical *ATPIA3* enrichment**

310 Despite the high degree of compartmentalization of cell types into laminae, biological  
311 processes in the developmental neocortex are highly dynamic, and cellular compartments are  
312 heterogeneous in cell-type composition. Single-cell RNA sequencing enables large-scale,  
313 simultaneous comparisons of gene expression across thousands of individual cells, thus bridging  
314 functional data from human genetics, immunohistochemistry, and cell-type-specific biology  
315 (Macosko et al., 2015). To this end, we performed Drop-seq on 125,942 individual cells from a 21  
316 wpc human neocortex (**Figure 4A & S2A**). Given the general trend of perisylvian to frontal  
317 cortex localization of the PMG phenotypes described in this study, we sought to investigate  
318 *ATPIA3* expression across presumptive neocortical areal domains. To build our single-cell  
319 expression dataset, we collected cells from 11 adjacent sections spanning the dorso-medial and  
320 rostro-caudal axes of the neocortex, validating and refining the positional identity of these serial  
321 samples using the graded expression of cortical patterning genes as benchmarks (**Figure 4B &**  
322 **S2**)(Sun et al., 2005). Using unsupervised statistical methods (see materials and methods), cells  
323 were partitioned into four transcriptionally distinct clusters, corresponding to the major neural cell  
324 classes in the midgestational neocortex: excitatory neurons (EN), inhibitory neurons (IN), neural  
325 progenitor cells (NPCs), and glia (**Figure 4C & S2C**). We excluded from this analysis all non-  
326 neural cell types as our scope of inquiry was specifically regarding *ATPIA3* dysfunction in  
327 neurons, and non-neural expression of *ATPIA3* is limited (**Figure 3B & S2**). Within each of the

Smith et al.,  
328 main neuronal cell classes we could further resolve transcriptionally distinct cell subtypes and  
329 states, which we interpreted by the distinctive enrichment of marker genes in each group (**Figure**  
330 **S2C**). Among ENs, consistent with the developmental landscape of mid-gestational corticogenesis  
331 described above, we could identify newborn and migratory upper-layer ENs at different stages of  
332 differentiation (clusters EN.0-3), and post-migratory deep-layer ENs expressing marker genes of  
333 maturing layer 6-5, including markers of resident SP neurons (EN-4, **Figure 4C**). Across cortical  
334 regions, *ATPIA3* expression was virtually undetectable in the NPC clusters, low in INs and glia,  
335 more highly expressed in ENs (**Figure 4C, S2C & D**), and – among ENs – highest in the EN-4  
336 cluster.

337 The EN-4 cluster was composed of cells sourcing from all cortical regions, and was marked  
338 by enriched expression of SP-specific genes (*CRYM* and *LPL*, **Figure 4C**), as well as by the  
339 expression of genes associated with neuronal maturation (e.g. axonal genes *NEFL/NEFM* and  
340 synaptic genes *SEMA3E*). This is consistent with the notion that the earliest-born neurons (a subset  
341 of which will persist in L6b in the adult cortex) settle and mature early in the developing  
342 SP(Hoerder-Suabedissen and Molnár, 2013). Within this cluster, *ATPIA3* appeared to be  
343 differentially expressed across cortical region, with highest expression levels found in cells from  
344 frontal samples, intermediate levels in cells from medial samples, and lowest levels in cells  
345 sampled from more caudal cortical regions (**Figure 4C & S2A**). In agreement with this, expression  
346 of *ATPIA3* in the EN-4 cluster was found to be enriched in neurons co-expressing SP markers and  
347 frontal cortex markers, but much less so in neurons expressing caudal cortex markers (**Figure 4D,**  
348 **S2 & S3**).

349 Cortical development proceeds along a rostral-to-caudal maturation gradient, with  
350 asynchronous growth patterns accounting for the differential expansion of frontal and caudal

Smith et al.,  
351 cortical regions(Rakic, 1974). This implies that, at any given time, neurons in frontal regions are  
352 on average more mature than their caudal counterparts. To investigate whether the observed  
353 *ATPIA3* enrichment in the EN-4 cluster might reflect a differential maturation state of EN neurons  
354 along the rostrocaudal axis, we performed pseudotime analysis of *ATPIA3* across all ENs. To do  
355 this, we used the Monocle3 algorithm, an established analytical tool allowing single-cell  
356 transcriptomes to be ordered and connected along a branched topology based on the differential  
357 expression of variable genes(Cao et al., 2019). By selecting as an “origin” cell, this algorithm  
358 allows projection of a “pseudo-differentiation” trajectory onto the network topology(Camp et al.,  
359 2015). This analysis revealed a positive correlation between *ATPIA3* expression and EN  
360 differentiation, suggesting *ATPIA3* may be required during neuronal differentiation, as neurons  
361 transition to a mature state, most readily observed in resident subplate neurons (**Figure 4E & F**).

362 Finally, to identify potential isoform-specific and cell-type specific vulnerabilities to  
363 *ATPIA1-3* variants during corticogenesis, we compared the expression patterns of the *ATPIA1-3*  
364 paralogs across cell clusters (**Figure S3A**). We find that expression of *ATPIA2* is restricted to  
365 NPCs (and specifically to radial glia), and is virtually undetectable in neurons – in an almost  
366 mutually-exclusive pattern to *ATPIA3*. *ATPIA1* expression more closely mimicked *ATPIA3*  
367 expression, albeit its expression in NPCs was higher, and partially overlapped *ATPIA2* (**Figure**  
368 **S3A**). Accordingly, pairwise correlation analysis of the three isoforms across clusters revealed that  
369 expression of *ATPIA1* and *ATPIA3* correlates more strongly with the EN-4-SP cluster, while  
370 expression of *ATPIA1* and *ATPIA2* correlates more highly with NPC clusters (**Figure S3B**).  
371 Across all cells, pairwise correlation analysis indicated a positive correlation, though moderate,  
372 between *ATPIA1* and *ATPIA3*, but weak-to-no correlation between *ATPIA1* and *ATPIA2*, and  
373 between *ATPIA2* and *ATPIA3* (**Figure S3C**). Together, this analysis suggests that neurons



Smith et al.,  
374 transitioning within the fetal SP may be particularly susceptible to *ATPIA3* variants, with  
375 potential broad consequences for cortical lamination. Moreover, the single cell variable expression  
376 of ATPase isoforms could underlie compensation or vulnerability mechanisms for disease  
377 haploinsufficiency or differential penetrance within specific cell populations.

378

379 ***ATPIA3* enrichment in parvalbumin interneurons and excitatory neurons in infant**  
380 **neocortex**

381 Given that *ATPIA3* expression persists in the postnatal neocortex (**Figure 3B**), and that  
382 several known *ATPIA3* mutations show postnatal onset of symptoms (Brashear et al., 1993;  
383 Smedemark-Margulies et al., 2016), we profiled *ATPIA3* expression in the infant neocortex. Using  
384 Drop-seq, we profiled 51,878 nuclei from a ~8-month-old human cortex, sampled from prefrontal,  
385 temporal, occipital, and parietal lobes (**Figure 5A**). Unsupervised hierarchical clustering sorted  
386 nuclear transcriptomes into 3 major classes – ENs, INs, and glia – subdivided into 24  
387 transcriptionally distinct cell classes (**Figure 5A & S4**). Within the EN clade, clusters stratified  
388 largely by layer and neuronal subtype, rather than cortical area, with several clusters enriched in  
389 gene markers of deep layer 5 and 6 (**Figure 5B**, See supplemental **S4** for full clading). Within the  
390 IN clade, cells stratified by developmental origin (Caudal or Medial Ganglionic Eminence) and  
391 major “cardinal types”, according to previous studies (Mayer et al., 2018). In the infant neocortex,  
392 like in the fetal neocortex, *ATPIA3* was also enriched in neurons compared to glia, but unlike in  
393 the fetal dataset, *ATPIA3* was more highly expressed in INs than in ENs (**Figure 5B & S5**). Among  
394 neuronal clusters, and across cortical regions, *ATPIA3* expression was fairly variable, with lowest  
395 expression in V1/occipital cortex cells, and wide range of expression levels within deep and upper  
396 layer EN clusters (**Figure 5B**). No specific enrichment was found in L6b ENs (i.e. the postnatal

Smith et al.,

397 remnant of the fetal SP layer), suggesting that fetal enrichment of *ATPIA3* in the SP is transient,  
398 with maturation and migration of cells continuing to populate the upper layers. Of note, the lack  
399 of specific enrichment in postnatal SP may reflect the fact that, unlike the fetal dataset, the  
400 postnatal dataset was built from nuclear RNA rather than whole cell RNA, so that some transcripts  
401 may be under-detected, primarily those localized primarily in the somato-dendritic compartment.

402         Across INs clusters, expression of *ATPIA3* was highest in cells sampled from the frontal  
403 lobe (prefrontal BA10), and more strikingly so within Parvalbumin (PV<sup>+</sup>) INs (**Figure 5B & S4C**).  
404 This differential expression pattern raised the hypothesis that *ATPIA3* may be required  
405 dynamically across neuronal types, cell-biological processes, and across developmental ages. To  
406 gain insights into the nature of the cell-biological signature associated with *ATPIA3* expression,  
407 we compared the top-100 genes correlating with *ATPIA3* in EN and IN clusters. Interestingly, we  
408 found that 50/100 *ATPIA3*-correlating genes were shared across cell types, suggesting that  
409 *ATPIA3* partakes in similar transcriptional programs, and thus potentially similar function, in  
410 different neuronal types. In both EN and IN, among the top genes correlating with *ATPIA3*, was  
411 *FXDY6*, the FXYD subunit of the ATPase complex (**Figure 5D**). We did find, however, that the  
412 ATPase  $\beta$  subunit beta subunit *ATPIB1* correlated with *ATPIA3* only in ENs, and *ATPIB2* in INs,  
413 suggesting that, at least in part, *ATPIA3* may form cell-type specific ATPase complexes in  
414 different neuronal classes (**Figure 5D**). Gene Ontology Enrichment analysis of the top 100-genes  
415 most strongly correlated with *ATPIA3* in both ENs and INs revealed significant over-  
416 representation of gene products associated with transmembrane ionic transport and the  
417 somatodendritic compartment, including synaptic vesicles (**Table S2**). This is consistent with the  
418 established role of *ATPIA3* in synaptic transmission and membrane potential, and suggests

Smith et al.,

419 *ATPIA3* may partake in a shared transcriptional network for which *ATPIA3* variants may perturb  
420 aspects of neuronal physiology central to many cell types.

421         Given the association of *ATPIA3* pathological variants with phenotypes affecting higher-  
422 order cognitive functions with no clear counterpart in animal models, it was of interest to  
423 investigate the degree to which *ATPIA3* enrichment in INs may be conserved among humans, non-  
424 human primates, and rodents. We took advantage of a recently published single-cell RNAseq  
425 dataset profiling gene expression in homologous IN types in humans, non-human primates  
426 (macaques and marmosets) and mice (Krienen et al., 2019). We found that relative *ATPIA3*  
427 expression levels across IN types, both in the neocortex and in the striatum, are largely conserved  
428 across species, with highest expression in the fast spiking PV<sup>+</sup> INs (**Figure S6**). This suggests that  
429 the observed differential expression of *ATPIA3* across neuronal types is genetically encoded and  
430 evolutionarily conserved.

431

432

Smith et al.,

433 **DISCUSSION**

434 Mutations in *ATPIA3*, the gene encoding the Na,K-ATPase  $\alpha_3$  catalytic subunit, have been  
435 associated with a wide spectrum of neurological diseases affecting childhood development,  
436 ranging in onset age from early infancy to late adolescence into adulthood. Here, we describe  
437 *ATPIA3* pathogenic variants in individuals presenting with PMG, a severe prenatal malformation  
438 of the cerebral cortex characterized by abnormal gyrification and laminar organization. These case  
439 studies extend the known phenotypic range of *ATPIA3*-related diseases, and provide new insights  
440 into the molecular pathology of PMG and PMG-associated developmental channelopathies.  
441 Furthermore, by compiling a single-cell atlas of *ATPIA3* expression in the fetal and early postnatal  
442 neocortex, we revealed cell-type-specific *ATPIA3* expression in the fetal and infant human brain,  
443 establishing a spatiotemporal roadmap for future genotype-phenotype associations studies, and  
444 studies of *ATPIA3* function in the subplate and cortical interneurons.

445 *ATPIA3* associated conditions comprise a broad spectrum of overlapping phenotypes,  
446 including the blending of encephalopathies with more paroxysmal phenotypes, with a complex  
447 genotype-phenotype correlation. Further confounding the genotype to phenotype relationship,  
448 identical amino acid substitutions can impart variable presentations (**Table S3**); for example,  
449 Leu924Pro and Gln851Arg reported here have been previously associated with EIEE and AHC  
450 without MCDs(Arystarkhova et al., 2019; Masoud et al., 2017), but with postnatal microcephaly  
451 (Leu924Pro), suggesting pathogenic susceptibility differs between individuals. Differential  
452 penetrance between individuals may reflect  $\alpha_3$  ATPase expression levels, competition between  
453 disease and wild-type  $\alpha_3$  subunits for utilization within Na/K-ATPases(Arystarkhova et al., 2019),  
454 and as described in this study, variable expression of  $\alpha_3$  (and coexpression with other  $\alpha$  and  $\beta$   
455 subunits) within different cell populations (**Figure 4D, S3 & S5**). Individuals with heterozygous

Smith et al.,

456 *ATPIA3* variants presented here with PMG also exhibited a range of phenotype severity, from  
457 unilateral to extensive bilateral PMG, variable degrees of developmental delay, postnatal  
458 microcephaly, ataxia-like phenotypes and EIEE. *ATPIA3*'s wide phenotypic spectrum is similar  
459 to known glutamate and sodium channel “developmental channelopathies”, in which a subset of  
460 cases present with EIEE and developmental delay, both with and without MCDs and postnatal  
461 microcephaly(Smith and Walsh, 2020). Taken together, *ATPIA3* PMG-associated variants likely  
462 represent a continuum of LOF features, with the more severe phenotype reflecting more complete  
463 LOF than for some other *ATPIA3*-associated conditions. In a future opportunity to examine  
464 cortical tissue of PMG associated with *ATPIA3* variants, it would be useful to document cortical  
465 architecture, including whether gaps occur in the pia mater and glia limitans. This anatomical  
466 defect permits continuity between the molecular zones of adjacent microgyri for synaptic  
467 excitatory short-circuitry leading to epilepsy, as with other genetic mutations in PMG(Jansen et  
468 al., 2016).

469 Functional analysis of *ATPIA3* variants associated with postnatal diseases are largely  
470 described as LOF; including decreased membrane localization in Leu924Pro, causing toxic effects  
471 within cells(Arystarkhova et al., 2019). LOF mechanisms described for *ATPIA3* disease-causing  
472 variants include changes in Na<sup>+</sup> affinity, impaired conformational changes, voltage-dependence  
473 shifts, and disruption of protein expression(Arystarkhova et al., 2019; Heinzen et al., 2014; M. Li  
474 et al., 2015). Since the Na,K-ATPase exports Na<sup>+</sup>, and elevated Na<sup>+</sup> can be deleterious to cellular  
475 processes(Azarias et al., 2013; Toustrup-Jensen et al., 2014),  $\alpha 3$  dysfunction that results in a shift  
476 in Na<sup>+</sup> affinity could trigger a known developmental pathophysiology associated with increased  
477 intracellular Na<sup>+</sup> concentration, leading to PMG (Smith et al., 2018; Smith and Walsh, 2020;  
478 Zaman et al., 2020). While some *ATPIA1* variants have been described to increase inward leak of

Smith et al.,  
479 Na<sup>+</sup>(Azizan et al., 2013; Kaneko et al., 2014), similar pathogenic gain of function effects have not  
480 been described in *ATPIA3* related diseases. In addition to acute ATPase pump dysfunction, PMG  
481 pathophysiology could also reflect an accelerated activation of toxic downstream mechanisms that  
482 underlie postnatal *ATPIA3*-related disorders causing neurodegeneration or cell death, including  
483 postnatal microcephaly(Paciorkowski et al., 2015), regional neuronal loss(Oblak et al., 2014), and  
484 cerebellar hypoplasia(Sweadner et al., 2016; Uchitel et al., 2019). Moreover, two of the PMG-  
485 causing *ATPIA3* variants we describe are located in the TM7-TM8 extracellular segment of the  
486  $\alpha 3$  that interacts with the  $\beta$ -subunit(Shinoda et al., 2009) and Leu924Pro demonstrates  $\beta$  subunit  
487 associated LOF membrane localization properties(Arystarkhova et al., 2019), suggesting the final  
488 formation of  $\alpha$ - $\beta$  complex could potentially underlie the pathophysiology. The  $\beta$ -subunit supports  
489 localization of the  $\alpha$ -subunit to the plasma membrane and modulates affinity of Na<sup>+</sup> and K<sup>+</sup> for the  
490 ATPase(Blanco et al., 1998). Moreover,  $\alpha$ - and  $\beta$ - subunits can trigger several intracellular  
491 signaling pathways associated with MCDs, including MAPK and AKT signaling via  
492 phosphoinositide 3-kinase (PI3K) and EGFR pathways, resulting in changes in cell polarity,  
493 growth, motility and gene expression(Z. Li and Langhans, 2015).

494 During embryonic brain development, bioelectric cellular properties are required for the  
495 propagation of key organizing signals, directly implicating ion channels and pumps in a variety of  
496 morphogenetic processes(Levin et al., 2017). For instance, in mice and ferrets, experimental  
497 modulations in membrane conductance and Na<sup>+</sup>-dependent excitation have been linked to neuronal  
498 fate specification and directed migration(Hurni et al., 2017; LoTurco et al., 1995; Smith et al.,  
499 2018; Vitali et al., 2018). The fetal SP represents a hub for the spatiotemporal integration and  
500 transduction of signals from many cellular sources. Early electrical activity patterns in the SP  
501 accompany the dynamic formation of transient synaptic networks between resident SP neurons

Smith et al.,  
502 and migratory ENs and INs en route to the CP, ascending radial glia processes, and ingressing  
503 thalamic fibers<sup>23,46</sup>. Our finding that (i) *ATPIA3*-expressing cells are located in the developing SP  
504 (ISH, Fig 3D), and (ii) co-express SP-specific marker genes (DropSeq, Fig 4 and S2), is therefore  
505 consistent with a role for *ATPIA3* in regulating electric activity within this compartment. This is  
506 consistent with the notion that human SP neurons possess large Na<sup>+</sup> currents with prolonged  
507 depolarized states(Moore et al., 2009), and therefore require a stout mechanism to recover Na<sup>+</sup> and  
508 K<sup>+</sup> electrochemical gradients following excitation, a known key function of the  $\alpha 3$  ATPase in  
509 postnatal neurons(Kim et al., 2004; Picton et al., 2017; Vaillend et al., 2002). In addition, the  
510 finding that *ATPIA3*-expressing cells are also found in the inner aspect of the CP (ISH, Fig 2C),  
511 express L6-5 EN markers (DropSeq, Fig4C), together with the rostral-to-caudal gradient of  
512 *ATPIA3* expression and positive correlation with neuronal pseudo-age, (Monocle, Fig 4F), all are  
513 consistent with a role of *ATPIA3* in the maturation of early-born deep-layer ENs.

514 The observed differential prenatal expression of Na<sup>+</sup>,K<sup>+</sup>,ATPase isoforms parallels the  
515 enrichment pattern reported for specific glutamate and sodium channel subtypes implicated in  
516 developmental channelopathies. These glutamate and sodium channel diseases maintain robust  
517 RNA expression of developmental subtypes; specific channel subtypes are utilized for  
518 developmental electrical functions (*SCN3A*, *GRIN2B*), whereas others are used for adult electrical  
519 functions (*SCN1A*, *GRIN2A*)(Smith and Walsh, 2020). The  $\alpha 3$  isoform may have a similar  
520 specialized function in fetal brain neurons compared to  $\alpha 1$  isoforms. For example, Na<sup>+</sup> affinity is  
521 lower in  $\alpha 3$  than  $\alpha 1$  isoforms(Azarias et al., 2013; Dobretsov and Stimers, 2005), enabling  $\alpha 3$   
522 containing ATPase pumps to respond to larger Na<sup>+</sup> influxes. Lower Na<sup>+</sup> affinity provides a wider  
523 range to buffer aberrant Na<sup>+</sup> flux, therefore could provide an evolutionarily advantageous  
524 neuroprotective effect in cells during development. Known developmental channelopathy genes

Smith et al.,  
525 also maintain a robust cell type and subtype expression profiles as *ATPIA3*; for example, *SCN3A*  
526 and *GRIN2B* are enriched in excitatory neurons and some progenitor types (Bagasrawala et al.,  
527 2017; Smith et al., 2018; Smith and Walsh, 2020), before transitioning to mostly *GRIN2A*-  
528 containing glutamate receptors and *SCN1A* in the postnatal cortex (Bagasrawala et al., 2017; Smith  
529 and Walsh, 2020). Intriguingly, the observed sc-RNA-seq *ATPIA2* enrichment in NPCs could  
530 offer a pathological basis for *ATPIA2* variants associated with fetal or early life demise, including  
531 microcephaly (Chatron et al., 2019; Monteiro et al., 2019).

In the postnatal cortex, the observed *ATPIA3* enrichment in interneurons likely supports  
532 physiological processes necessary for maintaining inhibitory tone of cortical circuits (Z. Li and  
533 Langhans, 2015), a proposed mechanism underlying EIEE, or perhaps AHC. We were surprised to  
534 find that even after 90 million years of divergence, the human and rodent postnatal cortex possess  
535 similar single-cell distribution of *ATPIA3*, most notably in PV<sup>+</sup> INs, underscoring the utility of  
536 mice as a model for studying excitatory/inhibitory balance (Bøttger et al., 2011), especially in the  
537 context of PV IN loss relating to postnatal brain disorders (Hunanyan et al., 2018). On the other  
538 hand, while *ATPIA3* expression in INs appears to be conserved, differences in circuits and  
539 connectivity, and how interneurons shape gene expression differentially could offer pathological  
540 differences between species. For example, the observed layer specific rostral enrichment of  
541 *ATPIA3* could contribute an early susceptibility for *ATPIA3* variants associated childhood onset  
542 schizophrenia (Chaumette et al., 2018; Smedemark-Margulies et al., 2016). Intriguingly, the  
543 identified *ATPIA3* enriched cell types in the pre- and postnatal cortex (subplate and PV<sup>+</sup> neurons),  
544 and Purkinje cells of the cerebellum, are all characterized by their robust firing properties (Moore  
545 et al., 2009; Tremblay et al., 2016). Within these cell types with dynamic physiological needs, the  
546 low affinity  $\alpha 3$  would help maintain ionic gradients following excitation and suggests neurons with  
547



Smith et al.,  
548 higher neurophysiological demands would be most susceptible to Na<sup>+</sup>,K<sup>+</sup>,ATPase dysfunction.  
549 Additionally, even within the cortical pyramidal neuron population, differential Na<sup>+</sup>,K<sup>+</sup>,ATPase  
550 activity levels exists (Anderson et al., 2010). Therefore, *ATPIA3* PMG-associated variants are  
551 likely LOF (affecting levels of Na<sup>+</sup> accumulation in cells), with severe phenotypes reflecting more  
552 complete LOF effects and toxicity within more vulnerable cell types.  
553

Smith et al.,

554 **ACKNOWLEDGMENTS**

555 We are grateful to the participant families presented here and thank members of the Walsh lab for  
556 helpful discussions and Johnathan Hecht for assistance with human tissue. Human tissue was  
557 obtained from the NIH Neurobiobank at the University of Maryland, Baltimore, MD. This work  
558 was supported by NIH F32NS100033801 and K99NS112604 (R.S.S.), NIH T32GM007753  
559 (S.K.A.), Paul G. Allen Frontiers Program and NIH R01NS032457 and R01NS035129 (C.A.W.),  
560 and BCH IDDRC U54 HD090255. This work was also supported by the Broad Center for  
561 Mendelian Genomics (UM1 HG008900) funded by the National Human Genome Research  
562 Institute (NHGRI) and the Tommy Fuss Foundation (R.S.S and J.G-H.). C.A.W. is an Investigator  
563 of the Howard Hughes Medical Institute.

564

565

566

567 **AUTHOR CONTRIBUTIONS**

568 C.A.W., A.J.B., R.S.S., S.K.A., F.P.V., E.M., L.F.S. and L.B. collected and evaluated clinical data;  
569 J.E.N. coordinated clinical data; R.S.S. performed and analyzed tissue experiments; M.F. and  
570 R.S.S. performed cortical dissections; M.G., C.D.M., N.R. and M.F. generated Drop-Seq libraries;  
571 M.F. analyzed Drop-Seq data; R.S.S., M.F., J.E.N., S.K.A. and C.A.W. wrote the manuscript, with  
572 contributions from all co-authors. We thank Kathleen Sweadner for productive discussion. The  
573 authors declare no competing financial interests.

574

575

576

577

578

579

580 **MAIN FIGURES**

581

582 **Figure 1.**

583 *ATPIA3* variants associated with cerebral cortex malformations

584

585 **Figure 2.**

586 Schematic of *ATPIA3* variants associated with cerebral cortex malformations and other

587 *ATPIA3* related diseases

588

589 **Figure 3.**

590 *ATPIA3* is differentially enriched to the human fetal period and localized to subplate and

591 deep-layer neurons

592

593 **Figure 4.**

594 Single cell *ATPIA3* expression in the developing human cerebral cortex

595 **Figure 5.**

596 Single-cell analysis of *ATPIA3* expression in the infant human neocortex

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611 FIGURES 1 - 5





Figure 1. *ATP1A3* variants associated with cerebral cortex malformations

Smith et al.,

612 **Figure 1. *ATPIA3* variants associated with cerebral cortex malformations**

613 **(A)** MRI images of Case A, B, C and D showing the cortical malformation, polymicrogyria (PMG).

614 White arrows denote gross location of affected brain regions. The Control image comes from an

615 unaffected 11-year-old. Scale bar (1cm) **(B)** Pedigrees with novel *de novo* pathogenic single

616 nucleotide variants in *ATPIA3*: Case A (missense, p.Arg901Met) with bilateral frontoparietal

617 PMG, Case B (splice donor site, c.2921+1G>A) with extensive bilateral PMG, Case C (missense,

618 p.Leu924Pro) with unilateral PMG, and Case D (missense, p.Gly851Arg) with extensive bilateral

619 PMG, more pronounced in the right hemisphere. Individual features: Genotype (-/+ , *de novo*

620 heterozygous), PMG, infantile seizures, developmental delay, and postnatal microcephaly shown

621 in pedigree summary. Square, male; circle, female; black and/or gray shading, affected individual.

622 See supplemental text for genetic validation and comprehensive clinical phenotyping.

623

624

625

626

627

Smith et al.,




Figure 2. Schematic of *ATP1A3* variants associated with cerebral cortex malformations and other *ATP1A3*-related diseases

Smith et al.,

629 **Figure 2. Schematic of *ATP1A3* variants associated with cerebral cortex malformations and**  
630 **other *ATP1A3* related diseases**

631  
632 **(A)** Overview of the  $\alpha$  subunit (green) of the Na,K-ATPase with novel PMG alleles mapped  
633 (colored amino acids) and previous case report of PMG associated allele (Leu888Pro)(Gurrieri et  
634 al., 2016). Red, p.Leu888Pro (L888P); Orange, p.Arg901Met (R901M); Purple, p.Leu924Pro  
635 (L924P); Blue, p.Gln851Arg (Q851R). Image generated with PyMOL using Protein Databank  
636 2ZXE(Shinoda et al., 2009). **(B)** Transmembrane topology schematic of Na,K-ATPase for  
637 visualization of PMG causing variants, including  $\alpha$ ,  $\beta$ , and FXYD subunits. We also denote a  
638 variant enriched region TM7-TM8, where  $\beta$  subunits interact with the  $\alpha_3$  subunit in the  
639 extracellular TM7-TM8 segment Glu899, Gln904, and Gln905(Shinoda et al., 2009). **(C)**  
640 Overview of genotype-phenotype correlation of *ATP1A3* associated disease single nucleotide  
641 variants, phenotypes were grouped by primary symptomatic presentation: including early infantile  
642 epileptic encephalopathy (EIEE); alternating hemiplegia of childhood (ACH); cerebellar ataxia,  
643 areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS); rapid-onset dystonia-  
644 parkinsonism (RDP); and childhood onset schizophrenia (COS), and/or a cortical malformation  
645 syndrome (MCD+), cerebellar ataxia (CA). Alleles from several sources including(Arystarkhova  
646 et al., 2019; Brashear et al., 1993; Holm et al., 2016; Sweadner et al., 2019). See supplemental  
647 Figure S7 and Table S3 for complete allele to protein topology breakdown.


648

649

650

651

652




**Figure 3. *ATP1A3* is differentially enriched to the human fetal period and localized to subplate and deep-layer neurons**



Smith et al.,

654 **Figure 3. *ATPIA3* is differentially enriched to the human fetal period and localized to**  
655 **subplate and deep-layer neurons**

656 (A) Chromosome locations for CNS enriched Na<sup>+</sup>,K<sup>+</sup>-ATPase alpha isoforms, *ATPIA1* and  
657 *ATPIA2* (Chr1), and *ATPIA3* (Chr19). (B) RNA transcriptome analysis of bulk brain regions  
658 revealed *ATPIA3* transcripts are high during fetal gestational and persist postnatally. CNS  
659 expressed paralogous *ATPIA1* and *ATPIA2* paralogs show relative expression pattern changes  
660 during development, while *ATPIA4* is not expressed significantly in the brain. Raw transcriptome  
661 data for (B) from Allen Brain Atlas, presented as log<sub>2</sub> RPKM (reads per kilobase per million)  
662 values and a polynomial fit to average across time points (Jones et al., 2009). (C) *Left*, *ATPIA3*  
663 mRNA chromogenic *in situ* hybridization performed on 19 weeks post conception (pcw) coronal  
664 brain sections demonstrate highest *ATPIA3* expression in the human cortical plate (CP), and  
665 subplate region (SP). Scale bar left, 500µm. *Right*, Corresponding fluorescence imaging of 19 wpc  
666 fetal brain with cell type specific markers for intermediate progenitors (TBR2) and neural  
667 progenitors (vimentin, VIM) demonstrates *ATPIA3* transcripts are not present within cells of the  
668 sub-ventricular zone (SVZ) and ventricular zone (VZ). Arrows indicate high expressing neurons  
669 in deep cortical layers and subplate region. (D) Magnified image from (C) depicting high *ATPIA3*  
670 expressing subplate layer cells. (E) *Left*, Schematic of developing sagittal fetal cerebellum tissue  
671 section at 19 wpc demonstrates enrichment of *ATPIA3* in Purkinje cell layer. (i) *ATPIA3* mRNA  
672 fluorescence *in situ* at 19 wpc demonstrates highest expression in the Purkinje cell layer,  
673 colocalizing with Purkinje cell marker calbindin (CALB1, green). (ii), Zoomed fluorescence  
674 image, including labeling of external granule layer. Scale bar left, 50µm. DAPI stain for nuclei in  
675 blue. Scale bar 25µm. VZ, ventricular zone; SVZ, subventricular zone; IMZ, intermediate zone;  
676 SP, subplate; CP, cortical plate; PCL, purkinje cell layer; EGL, external granule layer.



**Figure 4. Single cell *ATP1A3* expression atlas in the developing human cerebral cortex**

Smith et al.,

678 **Fig 4. Single cell *ATPIA3* expression atlas in the developing human cerebral cortex**

679

680 (A) *Left*: Schematic showing a 21 post conception weeks (pcw) forebrain and location of regions  
681 sampled (for anatomical detail see fig. S2A). *Top*: dorsolateral view. *Bottom*: sagittal view. *Right*:  
682 Uniform Manifold Approximation and Projection (UMAP) of 125,943 single cells profiled by  
683 DropSeq. Each dot represents a cell, color-coded by sample of origin. Key: blue-to-red: frontal-  
684 to-caudal. Occ: Occipital; Par: Parietal; Temp: Temporal; Ins: Insula; Orb: Orbital; Str: Striatum;  
685 PFC: Prefrontal Cortex; V1: Primary Visual Cortex; Hp: Hippocampus; CGE: Caudal Ganglionic  
686 Eminence; MGE: Medial Ganglionic Eminence (B) Graded expression of areal marker genes  
687 *LMO3*, *LMO4* and *NR2F1* (COUP-TF1) across samples ordered caudal-to-rostral (x-axis). Gene  
688 expression (y-axis) was normalized by cell (divided by total UMIs/cell x 100k), then the mean  
689 value for each gene was aggregated by sample. Notice the opposite gradient of *LMO3* and *NR2F1*  
690 expression, and the U-shaped pattern of *LMO4* expression along the rostro-caudal axis. See fig.  
691 S2B for additional areal markers. (C) *Left*: Histogram showing relative expression of *ATPIA3* (x-  
692 axis) across cell clusters (y-axis). Notice enriched expression of *ATPIA3* in cluster EN.4-SP,  
693 containing subplate (SP) EN neurons (See **Fig. SC** and **H** for SP markers enriched in this cluster).  
694 Mean *ATPIA3* expression was aggregated by cluster, then rescaled from 0 to 1. Cell clusters are  
695 color-coded by cell type (blue: excitatory neurons (EN); gold: glia; blue: inhibitory neurons (IN);  
696 red: neural progenitor cells (NPC). See fig.SB for cluster markers and assignments. *Right*: Dot-  
697 plot showing *ATPIA3* expression across clusters split by areas of origin (x-axis; sample 1-11,  
698 ordered from caudal to rostral). Color scale codes for mean expression by group; size of the dots  
699 codes for percentage of cells expressing *ATPIA3* in each group. (D) *Top*, Violin-Boxplot showing  
700 differential expression of *ATPIA3* (y-axis) in the EN.4-SP cluster across three main cortical  
701 partitions (x-axis; Caudal: samples 1-3 (occipital cortex); Medial: samples 4-8 (including parietal

Smith et al.,  
702 and temporal cortex, and subcortical structures); Frontal: samples 9-11 (frontal cortex). Dots  
703 represent individual cells. Violins show probability density distributions; boxes show interquartile  
704 ranges; notches show confidence intervals around the median (horizontal lines). Outliers were  
705 trimmed. Mean expression of *ATPIA3* was aggregated by region, then log<sub>10</sub>-transformed. Notice  
706 the highest expression of *ATPIA3* in cells sampled from frontal cortex, and lowest expression in  
707 cells sampled from caudal cortex. *Bottom*: Nissl-stained frontal coronal section of a 21 paw  
708 forebrain highlighting anatomical position of SP. Source: Atlas of the Developing Human Brain,  
709 *BrainSpan* ([www.brainspan.org](http://www.brainspan.org)), Reference Atlas. **(E)** *ATPIA3* expression across cells in the EN  
710 clusters (color-coded in blue in C, left) ordered by pseudotime. Dots represent individual cells. Y-  
711 axis: log-transformed, scaled expression of *ATPIA3* by cell. X-axis: pseudotime score (color-  
712 coded) for each cell, calculated using the Monocle3 algorithm. Trend-line shows the increase of  
713 *ATPIA3* expression as function of pseudotime, calculated by fitting a quasipoisson model to the  
714 data. **(F)** UMAP of all profiled cells color-coded by cluster (see C, left). The EN.4-SP cluster is  
715 highlighted. **(G)** UMAP of cells in the EN.4-SP cluster (highlighted in F) color-coded by rostral,  
716 medial and caudal anatomical partition of origin (see also D, top). Notice that cells segregate by  
717 origin. **(H)** Relative expression of areal marker genes in the EN.4-SP cluster (see G). Relative  
718 gene expression is coded by color and size. Notice that *ATPIA3* is enriched in cells expressing SP  
719 markers (*CRYM*, *WNT7B*, *HS3ST4*) and frontal cortex markers (*GRP*, *SEMA3E*), but not caudal  
720 cortex markers (*NPY*, *LPL*, *NEFL*).

721

Smith et al.,




Figure 5. Single-cell analysis of *ATP1A3* expression in the infant human neocortex

Smith et al.,

722 **Figure 5. Single-cell analysis of *ATPIA3* expression in the infant human neocortex**

723 (A) *Left*, Schematic showing an 8-month-old neocortex and location of regions sampled. BA:  
724 Brodmann area; PFC: Prefrontal Cortex; V1: Primary Visual Cortex. *Right*, T-distributed  
725 Stochastic Neighbor Embedding (tSNE) of 51,878 single nuclei profiled by DropSeq. Each dot  
726 represents a nucleus, color-coded by cluster (*left*), cell type (*middle*) and origin sample (*right*). EN:  
727 excitatory neurons; IN: inhibitory neurons. See C for cluster and cell-class assignments. (B) *Top*,  
728 dendrogram summarizing hierarchical clustering of data. Clusters are color-coded as in A, left).  
729 See fig.S4 for cluster markers and assignments. *Middle*, bar graph showing relative expression of  
730 *ATPIA3* (y-axis) across cell clusters (x-axis). Mean expression was aggregated by cluster, then  
731 rescaled from 0 to 1 across all clusters. Data are color-coded by cell type (as in A, middle – blue:  
732 EN; gold: IN; brown: glia). *Bottom*, Dot-plot showing *ATPIA3* expression across the IN and EN  
733 clusters (x-axis) split by areas of origin (y-axis). Color scale codes for mean expression by group;  
734 size of the dots codes for percentage of cells expressing *ATPIA3* in each group. *Right*, tSNE plots  
735 showing specific enrichment of cortical marker genes including genes associated with early  
736 activity in the developing cortex (*MEFC2*, *SLC17A7* and *SLC17A6* (*VGLU1* and *VGLU2*), and  
737 MCD associated gene *TUBB2A*. (D) Venn diagram showing intersection between the top-100  
738 genes correlating with *ATPIA3* in the EN cluster (blue) and IN cluster (gold). 47/100 genes are  
739 shared between the two groups. Top 50 genes correlating with *ATPIA3* in the EN and IN clusters  
740 are shown. Dots indicate Pearson's R for each gene in the EN cluster (*top*; blue) and IN cluster  
741 (*bottom*; gold). Genes found in both groups are indicated in red, and the respective correlation  
742 coefficients are connected by red lines.

743

Smith et al.,

744 **REFERENCES**

- 745 Anderson, T.R., Huguenard, J.R., Prince, D.A., 2010. Differential effects of Na<sup>+</sup>-K<sup>+</sup> ATPase  
746 blockade on cortical layer V neurons. *The Journal of Physiology* 588, 4401–4414.  
747 doi:10.1113/jphysiol.2010.191858
- 748 Arystarkhova, E., Haq, I.U., Luebbert, T., Mochel, F., Saunders-Pullman, R., Bressman, S.B.,  
749 Feschenko, P., Salazar, C., Cook, J.F., Demarest, S., Brashear, A., Ozelius, L.J., Sweadner,  
750 K.J., 2019. Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding,  
751 and allele competition. *Neurobiology of Disease* 132, 104577.  
752 doi:10.1016/j.nbd.2019.104577
- 753 Azarias, G., Kruusmägi, M., Connor, S., Akkuratov, E.E., Liu, X.-L., Lyons, D., Brismar, H.,  
754 Broberger, C., Aperia, A., 2013. A specific and essential role for Na,K-ATPase  $\alpha$ 3 in  
755 neurons co-expressing  $\alpha$ 1 and  $\alpha$ 3. *J. Biol. Chem.* 288, 2734–2743.  
756 doi:10.1074/jbc.M112.425785
- 757 Azizan, E.A.B., Poulsen, H., Tuluc, P., Zhou, J., Clausen, M.V., Lieb, A., Maniero, C., Garg, S.,  
758 Bochukova, E.G., Zhao, W., Shaikh, L.H., Brighton, C.A., Teo, A.E.D., Davenport, A.P.,  
759 Dekkers, T., Tops, B., Küsters, B., Ceral, J., Yeo, G.S.H., Neogi, S.G., McFarlane, I.,  
760 Rosenfeld, N., Marass, F., Hadfield, J., Margas, W., Chaggar, K., Solar, M., Deinum, J.,  
761 Dolphin, A.C., Farooqi, I.S., Striessnig, J., Nissen, P., Brown, M.J., 2013. Somatic mutations  
762 in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. *Nat Genet*  
763 1–8. doi:10.1038/ng.2716
- 764 Bagasrawala, I., Memi, F., V Radonjić, N., Zecevic, N., 2017. N-Methyl d-Aspartate Receptor  
765 Expression Patterns in the Human Fetal Cerebral Cortex. *Cereb. Cortex* 27, 5041–5053.  
766 doi:10.1093/cercor/bhw289
- 767 Blanco, G., Sánchez, G., Mercer, R.W., 1998. Differential regulation of Na,K-ATPase isozymes  
768 by protein kinases and arachidonic acid. *Arch. Biochem. Biophys.* 359, 139–150.  
769 doi:10.1006/abbi.1998.0904
- 770 Brashear, A., Sweadner, K.J., Cook, J.F., Swoboda, K.J., Ozelius, L., 1993. ATP1A3-Related  
771 Neurologic Disorders. *GeneReviews Internet*.  
772 doi:<https://www.ncbi.nlm.nih.gov/books/NBK1115/>
- 773 Böttger, P., Tracz, Z., Heuck, A., Nissen, P., Romero-Ramos, M., Lykke-Hartmann, K., 2011.  
774 Distribution of Na/K-ATPase alpha 3 isoform, a sodium-potassium P-type pump associated  
775 with rapid-onset of dystonia parkinsonism (RDP) in the adult mouse brain. *J. Comp. Neurol.*  
776 519, 376–404. doi:10.1002/cne.22524
- 777 Camp, J.G., Badsha, F., Florio, M., Kanton, S., Gerber, T., Wilsch-Bräuninger, M., Lewitus, E.,  
778 Sykes, A., Hevers, W., Lancaster, M., Knoblich, J.A., Lachmann, R., Pääbo, S., Huttner,  
779 W.B., Treutlein, B., 2015. Human cerebral organoids recapitulate gene expression programs  
780 of fetal neocortex development. *Proc Natl Acad Sci USA* 201520760–6.  
781 doi:10.1073/pnas.1520760112
- 782 Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D.M., Hill, A.J., Zhang, F., Mundlos, S.,  
783 Christiansen, L., Steemers, F.J., Trapnell, C., Shendure, J., 2019. The single-cell  
784 transcriptional landscape of mammalian organogenesis. *Nature* 566, 496–502.  
785 doi:10.1038/s41586-019-0969-x
- 786 Chatron, N., Cabet, S., Alix, E., Buenerd, A., Cox, P., Guibaud, L., Labalme, A., Marks, P.,  
787 Osio, D., Putoux, A., Sanlaville, D., Lesca, G., Vasiljevic, A., 2019. A novel lethal  
788 recognizable polymicrogyric syndrome caused by ATP1A2 homozygous truncating variants.  
789 *Brain* 142, 3367–3374. doi:10.1093/brain/awz272

Smith et al.,

- 790 Chaumette, B., Ferrafiat, V., Ambalavanan, A., Goldenberg, A., Dionne-Laporte, A.,  
791 Spiegelman, D., Dion, P.A., Gerardin, P., Laurent, C., Cohen, D., Rapoport, J., Rouleau,  
792 G.A., 2018. Missense variants in ATP1A3 and FXYD gene family are associated with  
793 childhood-onset schizophrenia. *Mol Psychiatry* 22, 539. doi:10.1038/s41380-018-0103-8  
794 Clausen, M.V., Hilbers, F., Poulsen, H., 2017. The Structure and Function of the Na,K-ATPase  
795 Isoforms in Health and Disease. *Front Physiol* 8, 371. doi:10.3389/fphys.2017.00371  
796 Dobretsov, M., Stimers, J.R., 2005. Neuronal function and alpha3 isoform of the Na/K-ATPase.  
797 *Front. Biosci.* 10, 2373–2396. doi:10.2741/1704  
798 Fry, A.E., Fawcett, K.A., Zelnik, N., Yuan, H., Thompson, B.A.N., Shemer-Meiri, L., Cushion,  
799 T.D., Mugalaasi, H., Sims, D., Stoodley, N., Chung, S.-K., Rees, M.I., Patel, C.V., Brueton,  
800 L.A., Layet, V., Giuliano, F., Kerr, M.P., Banne, E., Meiner, V., Lerman-Sagie, T., Helbig,  
801 K.L., Kofman, L.H., Knight, K.M., Chen, W., Kannan, V., Hu, C., Kusumoto, H., Zhang, J.,  
802 Swanger, S.A., Shaulsky, G.H., Mirzaa, G.M., Muir, A.M., Mefford, H.C., Dobyns, W.B.,  
803 Mackenzie, A.B., Mullins, J.G.L., Lemke, J.R., Bahi-Buisson, N., Traynelis, S.F., Iago, H.F.,  
804 Pilz, D.T., 2018. De novo mutations in GRIN1 cause extensive bilateral polymicrogyria.  
805 *Brain* 141, 698–712. doi:10.1093/brain/awx358  
806 Gurrieri, F., Tiziano, F.D., Zampino, G., Neri, G., 2016. Recognizable facial features in patients  
807 with alternating hemiplegia of childhood. *Am. J. Med. Genet. A* 170, 2698–2705.  
808 doi:10.1002/ajmg.a.37808  
809 Heinzen, E.L., Arzimanoglou, A., Brashear, A., Clapcote, S.J., Gurrieri, F., Goldstein, D.B.,  
810 Jóhannesson, S.H., Mikati, M.A., Neville, B., Nicole, S., Ozelius, L.J., Poulsen, H., Schyns,  
811 T., Sweadner, K.J., van den Maagdenberg, A., Vilsen, B., 2014. Distinct neurological  
812 disorders with ATP1A3 mutations. *The Lancet Neurology* 13, 503–514. doi:10.1016/S1474-  
813 4422(14)70011-0  
814 Hoerder-Suabedissen, A., Molnár, Z., 2013. Molecular diversity of early-born subplate neurons.  
815 *Cereb. Cortex* 23, 1473–1483. doi:10.1093/cercor/bhs137  
816 Holm, R., Toustrup-Jensen, M.S., Einholm, A.P., Schack, V.R., Andersen, J.P., Vilsen, B., 2016.  
817 Neurological disease mutations of  $\alpha 3$  Na<sup>+</sup>,K<sup>+</sup>-ATPase: Structural and functional  
818 perspectives and rescue of compromised function. *Biochim. Biophys. Acta* 1857, 1807–  
819 1828. doi:10.1016/j.bbabi.2016.08.009  
820 Hunanyan, A.S., Helseth, A.R., Abdelnour, E., Kherallah, B., Sachdev, M., Chung, L., Masoud,  
821 M., Richardson, J., Li, Q., Nadler, J.V., Moore, S.D., Mikati, M.A., 2018. Mechanisms of  
822 increased hippocampal excitability in the Mash1<sup>+/-</sup> mouse model of Na<sup>+</sup>/K<sup>+</sup>-ATPase  
823 dysfunction. *Epilepsia* 59, 1455–1468. doi:10.1111/epi.14441  
824 Hurni, N., Kolodziejczak, M., Tomasello, U., Badia, J., Jacobshagen, M., Prados, J., Dayer, A.,  
825 2017. Transient Cell-intrinsic Activity Regulates the Migration and Laminar Positioning of  
826 Cortical Projection Neurons. *Cereb. Cortex* 27, 3052–3063. doi:10.1093/cercor/bhx059  
827 Jansen, A.C., Robitaille, Y., Honavar, M., Mullatti, N., Leventer, R.J., Andermann, E.,  
828 Andermann, F., Squier, W., 2016. The histopathology of polymicrogyria: a series of 71 brain  
829 autopsy studies. *Dev Med Child Neurol* 58, 39–48. doi:10.1111/dmcn.12840  
830 Jones, A., Overly, C.C., Sunkin, S.M., 2009. The Allen Brain Atlas: 5 years and beyond. *Nat*  
831 *Rev Neurosci* 10, 821–828. doi:10.1038/nrn2722  
832 Kaneko, M., Desai, B.S., Cook, B., 2014. Ionic leakage underlies a gain-of-function effect of  
833 dominant disease mutations affecting diverse P-type ATPases. *Nature Publishing Group* 46,  
834 144–151. doi:10.1038/ng.2850



Smith et al.,

- 835 Kim, J., Ghosh, S., Liu, H., Tateyama, M., Kass, R.S., Pitt, G.S., 2004. Calmodulin mediates  
836 Ca<sup>2+</sup> sensitivity of sodium channels. *J. Biol. Chem.* 279, 45004–45012.  
837 doi:10.1074/jbc.M407286200
- 838 Krienen, F.M., Goldman, M., Zhang, Q., del Rosario, R., Florio, M., Machold, R., Saunders, A.,  
839 Levandowski, K., Zaniewski, H., Schuman, B., Wu, C., Lutservitz, A., Mullally, C.D., Reed,  
840 N., Bien, E., Bortolin, L., Fernandez-Otero, M., Lin, J., Wysoker, A., Nemesh, J., Kulp, D.,  
841 Burns, M., Tkachev, V., Smith, R., Walsh, C.A., Dimidschstein, J., Rudy, B., Kean, L.,  
842 Berretta, S., Fishell, G., Feng, G., McCarroll, S.A., 2019. Innovations in Primate Interneuron  
843 Repertoire. *bioRxiv* 76, 86–51. doi:10.1101/709501
- 844 Levin, M., Pezzulo, G., Finkelstein, J.M., 2017. Endogenous Bioelectric Signaling Networks:  
845 Exploiting Voltage Gradients for Control of Growth and Form. *Annu Rev Biomed Eng* 19,  
846 353–387. doi:10.1146/annurev-bioeng-071114-040647
- 847 Li, M., Jazayeri, D., Corry, B., McSweeney, K.M., Heinzen, E.L., Goldstein, D.B., Petrou, S.,  
848 2015. A functional correlate of severity in alternating hemiplegia of childhood.  
849 *Neurobiology of Disease* 77, 88–93. doi:10.1016/j.nbd.2015.02.002
- 850 Li, Z., Langhans, S.A., 2015. Transcriptional regulators of Na,K-ATPase subunits. *Front Cell*  
851 *Dev Biol* 3, 66. doi:10.3389/fcell.2015.00066
- 852 LoTurco, J.J., Owens, D.F., Heath, M.J., Davis, M.B., Kriegstein, A.R., 1995. GABA and  
853 glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. *Neuron* 15, 1287–  
854 1298.
- 855 Luhmann, H.J., Kirischuk, S., Kilb, W., 2018. The Superior Function of the Subplate in Early  
856 Neocortical Development. *Front Neuroanat* 12, 97. doi:10.3389/fnana.2018.00097
- 857 Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas,  
858 A.R., Kamitaki, N., Martersteck, E.M., Trombetta, J.J., Weitz, D.A., Sanes, J.R., Shalek,  
859 A.K., Regev, A., McCarroll, S.A., 2015. Highly Parallel Genome-wide Expression Profiling  
860 of Individual Cells Using Nanoliter Droplets. *Cell* 161, 1202–1214.  
861 doi:10.1016/j.cell.2015.05.002
- 862 Masoud, M., Gordon, K., Hall, A., Jasien, J., Lardinois, K., Uchitel, J., McLean, M., Prange, L.,  
863 Wuchich, J., Mikati, M.A., 2017. Motor function domains in alternating hemiplegia of  
864 childhood. *Dev Med Child Neurol* 59, 822–828. doi:10.1111/dmcn.13443
- 865 Mayer, C., Hafemeister, C., Bandler, R.C., Machold, R., Batista Brito, R., Jaglin, X., Allaway,  
866 K., Butler, A., Fishell, G., Satija, R., 2018. Developmental diversification of cortical  
867 inhibitory interneurons. *Nature* 555, 457–462. doi:10.1038/nature25999
- 868 McGrail, K.M., Phillips, J.M., Sweadner, K.J., 1991. Immunofluorescent localization of three  
869 Na,K-ATPase isozymes in the rat central nervous system: both neurons and glia can express  
870 more than one Na,K-ATPase. *Journal of Neuroscience* 11, 381–391.  
871 doi:10.1523/JNEUROSCI.11-02-00381.1991
- 872 Miller, J.A., Ding, S.-L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Ebbert, A., Riley, Z.L.,  
873 Royall, J.J., Aiona, K., Arnold, J.M., Bennet, C., Bertagnolli, D., Brouner, K., Butler, S.,  
874 Caldejon, S., Carey, A., Cuhaciyani, C., Dalley, R.A., Dee, N., Dolbeare, T.A., Facer,  
875 B.A.C., Feng, D., Fliss, T.P., Gee, G., Goldy, J., Gourley, L., Gregor, B.W., Gu, G., Howard,  
876 R.E., Jochim, J.M., Kuan, C.L., Lau, C., Lee, C.-K., Lee, F., Lemon, T.A., Lesnar, P.,  
877 McMurray, B., Mastan, N., Mosqueda, N., Naluai-Cecchini, T., Ngo, N.-K., Nyhus, J.,  
878 Oldre, A., Olson, E., Parente, J., Parker, P.D., Parry, S.E., Stevens, A., Pletikos, M., Reding,  
879 M., Roll, K., Sandman, D., Sarreal, M., Shapouri, S., Shapovalova, N.V., Shen, E.H.,  
880 Sjoquist, N., Slaughterbeck, C.R., Smith, M., Sodt, A.J., Williams, D., Zöllei, L., Fischl, B.,

- Smith et al.,
- 881 Gerstein, M.B., Geschwind, D.H., Glass, I.A., Hawrylycz, M.J., Hevner, R.F., Huang, H.,  
882 Jones, A., Knowles, J.A., Levitt, P., Phillips, J.W., Sestan, N., Wohnoutka, P., Dang, C.,  
883 Bernard, A., Hohmann, J.G., Lein, E.S., 2014. Transcriptional landscape of the prenatal  
884 human brain. *Nature* 1–19. doi:10.1038/nature13185
- 885 Monteiro, F.P., Curry, C.J., Hevner, R., Elliott, S., Fisher, J.H., Turocy, J., Dobyns, W.B., Costa,  
886 L.A., Freitas, E., Kitajima, J.P., Kok, F., 2019. Biallelic loss of function variants in ATP1A2  
887 cause hydrops fetalis, microcephaly, arthrogryposis and extensive cortical malformations.  
888 *Eur J Med Genet* 63, 103624. doi:10.1016/j.ejmg.2019.01.014
- 889 Moore, A.R., Filipovic, R., Mo, Z., Rasband, M.N., Zecevic, N., Antic, S.D., 2009. Electrical  
890 excitability of early neurons in the human cerebral cortex during the second trimester of  
891 gestation. *Cereb. Cortex* 19, 1795–1805. doi:10.1093/cercor/bhn206
- 892 Oblak, A.L., Hagen, M.C., Sweadner, K.J., Haq, I., Whitlow, C.T., Maldjian, J.A., Epperson, F.,  
893 Cook, J.F., Stacy, M., Murrell, J.R., Ozelius, L.J., Brashear, A., Ghetti, B., 2014. Rapid-  
894 onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a  
895 neuropathologic and neuroanatomical study of four siblings. *Acta Neuropathol.* 128, 81–98.  
896 doi:10.1007/s00401-014-1279-x
- 897 Paciorkowski, A.R., McDaniel, S.S., Jansen, L.A., Tully, H., Tuttle, E., Ghoneim, D.H., Tupal,  
898 S., Gunter, S.A., Vasta, V., Zhang, Q., Tran, T., Liu, Y.B., Ozelius, L.J., Brashear, A.,  
899 Sweadner, K.J., Dobyns, W.B., Hahn, S., 2015. Novel mutations in ATP1A3 associated with  
900 catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly.  
901 *Epilepsia* 56, 422–430. doi:10.1111/epi.12914
- 902 Picton, L.D., Nascimento, F., Broadhead, M.J., Sillar, K.T., Miles, G.B., 2017. Sodium Pumps  
903 Mediate Activity-Dependent Changes in Mammalian Motor Networks. *J. Neurosci.* 37, 906–  
904 921. doi:10.1523/JNEUROSCI.2005-16.2016
- 905 Platzer, K., Yuan, H., Schütz, H., Winschel, A., Chen, W., Hu, C., Kusumoto, H., Heyne, H.O.,  
906 Helbig, K.L., Tang, S., Willing, M.C., Tinkle, B.T., Adams, D.J., Depienne, C., Keren, B.,  
907 Mignot, C., Frengen, E., Strømme, P., Biskup, S., Döcker, D., Strom, T.M., Mefford, H.C.,  
908 Myers, C.T., Muir, A.M., LaCroix, A., Sadleir, L., Scheffer, I.E., Brilstra, E., van Haelst,  
909 M.M., van der Smagt, J.J., Bok, L.A., Møller, R.S., Jensen, U.B., Millichap, J.J., Berg, A.T.,  
910 Goldberg, E.M., De Bie, I., Fox, S., Major, P., Jones, J.R., Zackai, E.H., Abou Jamra, R.,  
911 Rolfs, A., Leventer, R.J., Lawson, J.A., Roscioli, T., Jansen, F.E., Ranza, E., Korff, C.M.,  
912 Lehesjoki, A.-E., Courage, C., Linnankivi, T., Smith, D.R., Stanley, C., Mintz, M.,  
913 McKnight, D., Decker, A., Tan, W.-H., Tarnopolsky, M.A., Brady, L.I., Wolff, M., Dondit,  
914 L., Pedro, H.F., Parisotto, S.E., Jones, K.L., Patel, A.D., Franz, D.N., Vanzo, R., Marco, E.,  
915 Ranells, J.D., Di Donato, N., Dobyns, W.B., Laube, B., Traynelis, S.F., Lemke, J.R., 2017.  
916 GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional  
917 consequences and treatment aspects. *Journal of Medical Genetics* 54, 460–470.  
918 doi:10.1136/jmedgenet-2016-104509
- 919 Rakic, P., 1974. Neurons in rhesus monkey visual cortex: systematic relation between time of  
920 origin and eventual disposition. *Science* 183, 425–427. doi:10.1126/science.183.4123.425
- 921 Shinoda, T., Ogawa, H., Cornelius, F., Toyoshima, C., 2009. Crystal structure of the sodium-  
922 potassium pump at 2.4 Å resolution. *Nature* 459, 446–450. doi:10.1038/nature07939
- 923 Simmons, C.Q., Thompson, C.H., Cawthon, B.E., Westlake, G., Swoboda, K.J., Kiskinis, E.,  
924 Ess, K.C., George, A.L., 2018. Direct evidence of impaired neuronal Na/K-ATPase pump  
925 function in alternating hemiplegia of childhood. *Neurobiology of Disease* 115, 29–38.  
926 doi:10.1016/j.nbd.2018.03.009

Smith et al.,

- 927 Smedemark-Margulies, N., Brownstein, C.A., Vargas, S., Tembulkar, S.K., Towne, M.C., Shi, J.,  
928 Gonzalez-Cuevas, E., Liu, K.X., Bilguvar, K., Kleiman, R.J., Han, M.-J., Torres, A., Berry,  
929 G.T., Yu, T.W., Beggs, A.H., Agrawal, P.B., Gonzalez-Heydrich, J., 2016. A novel de novo  
930 mutation in ATP1A3 and childhood-onset schizophrenia. *Cold Spring Harb Mol Case Stud* 2,  
931 a001008–13. doi:10.1101/mcs.a001008
- 932 Smith, R.S., Kenny, C.J., Ganesh, V., Jang, A., Borges-Monroy, R., Partlow, J.N., Hill, R.S.,  
933 Shin, T., Chen, A.Y., Doan, R.N., Anttonen, A.-K., Ignatius, J., Medne, L., Bönnemann,  
934 C.G., Hecht, J.L., Salonen, O., Barkovich, A.J., Poduri, A., Wilke, M., de Wit, M.C.Y.,  
935 Mancini, G.M.S., Sztriha, L., Im, K., Amrom, D., Andermann, E., Paetau, R., Lehesjoki, A.-  
936 E., Walsh, C.A., Lehtinen, M.K., 2018. Sodium Channel SCN3A (NaV1.3) Regulation of  
937 Human Cerebral Cortical Folding and Oral Motor Development. *Neuron*.  
938 doi:10.1016/j.neuron.2018.07.052
- 939 Smith, R.S., Walsh, C.A., 2020. Ion Channel Functions in Early Brain Development. *Trends in*  
940 *Neurosciences* 43, 103–114. doi:10.1016/j.tins.2019.12.004
- 941 Sun, T., Patoine, C., Abu-Khalil, A., Visvader, J., Sum, E., Cherry, T.J., Orkin, S.H., Geschwind,  
942 D.H., Walsh, C.A., 2005. Early asymmetry of gene transcription in embryonic human left  
943 and right cerebral cortex. *Science* 308, 1794–1798. doi:10.1126/science.1110324
- 944 Sweadner, K.J., Arystarkhova, E., Penniston, J.T., Swoboda, K.J., Brashear, A., Ozelius, L.J.,  
945 2019. Genotype-structure-phenotype relationships diverge in paralogs ATP1A1, ATP1A2,  
946 and ATP1A3. *Neurol Genet* 5, e303. doi:10.1212/NXG.0000000000000303
- 947 Sweadner, K.J., Toro, C., Whitlow, C.T., Snively, B.M., Cook, J.F., Ozelius, L.J., Markello,  
948 T.C., Brashear, A., 2016. ATP1A3 Mutation in Adult Rapid-Onset Ataxia. *PLoS ONE* 11,  
949 e0151429. doi:10.1371/journal.pone.0151429
- 950 Toustrup-Jensen, M.S., Einholm, A.P., Schack, V.R., Nielsen, H.N., Holm, R., Sobrido, M.-J.,  
951 Andersen, J.P., Clausen, T., Vilsen, B., 2014. Relationship between intracellular Na<sup>+</sup>  
952 concentration and reduced Na<sup>+</sup> affinity in Na<sup>+</sup>,K<sup>+</sup>-ATPase mutants causing neurological  
953 disease. *J. Biol. Chem.* 289, 3186–3197. doi:10.1074/jbc.M113.543272
- 954 Tremblay, R., Lee, S., Rudy, B., 2016. GABAergic Interneurons in the Neocortex: From Cellular  
955 Properties to Circuits. *Neuron* 91, 260–292. doi:10.1016/j.neuron.2016.06.033
- 956 Uchitel, J., Helseth, A., Prange, L., McLean, M., Ghusayni, R., Sachdev, M., Hunanyan, A.,  
957 Mikati, M.A., 2019. The epileptology of alternating hemiplegia of childhood. *Neurology* 93,  
958 e1248–e1259. doi:10.1212/WNL.00000000000008159
- 959 Vaillend, C., Mason, S.E., Cuttle, M.F., Alger, B.E., 2002. Mechanisms of neuronal  
960 hyperexcitability caused by partial inhibition of Na<sup>+</sup>-K<sup>+</sup>-ATPases in the rat CA1  
961 hippocampal region. *Journal of Neurophysiology* 88, 2963–2978. doi:10.1152/jn.00244.2002
- 962 Viollet, L., Glusman, G., Murphy, K.J., Newcomb, T.M., Reyna, S.P., Sweney, M., Nelson, B.,  
963 Andermann, F., Andermann, E., Acsadi, G., Barbano, R.L., Brown, C., Brunkow, M.E.,  
964 Chugani, H.T., Cheyette, S.R., Collins, A., DeBrosse, S.D., Galas, D., Friedman, J., Hood,  
965 L., Huff, C., Jorde, L.B., King, M.D., LaSalle, B., Leventer, R.J., Lewelt, A.J., Massart,  
966 M.B., Mérida, M.R., Ptáček, L.J., Roach, J.C., Rust, R.S., Renault, F., Sanger, T.D., Sotero  
967 de Menezes, M.A., Tennyson, R., Uldall, P., Zhang, Y., Zupanc, M., Xin, W., Silver, K.,  
968 Swoboda, K.J., 2015. Alternating Hemiplegia of Childhood: Retrospective Genetic Study  
969 and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry. *PLoS*  
970 *ONE* 10, e0127045. doi:10.1371/journal.pone.0127045
- 971 Vitali, I., Fièvre, S., Telley, L., Oberst, P., Bariselli, S., Frangeul, L., Baumann, N., McMahon,  
972 J.J., Klingler, E., Bocchi, R., Kiss, J.Z., Bellone, C., Silver, D.L., Jabaudon, D., 2018.

Smith et al.,

973 Progenitor Hyperpolarization Regulates the Sequential Generation of Neuronal Subtypes in  
974 the Developing Neocortex. *Cell* 1–29. doi:10.1016/j.cell.2018.06.036  
975 Zaman, T., Helbig, K.L., Clatot, J., Thompson, C.H., Kang, S.K., Stouffs, K., Jansen, A.E.,  
976 Verstraete, L., Jacquinet, A., Parrini, E., Guerrini, R., Fujiwara, Y., Miyatake, S., Ben Zeev,  
977 B., Bassan, H., Reish, O., Marom, D., Hauser, N., Vu, T.A., Ackermann, S., Spencer, C.E.,  
978 Lippa, N., Srinivasan, S., Charzewska, A., Hoffman Zacharska, D., Fitzpatrick, D., Harrison,  
979 V., Vasudevan, P., Joss, S., Pilz, D.T., Fawcett, K.A., Helbig, I., Matsumoto, N., Kearney,  
980 J.A., Fry, A.E., Goldberg, E.M., 2020. SCN3A-Related Neurodevelopmental Disorder: A  
981 Spectrum of Epilepsy and Brain Malformation. *Annals of Neurology*. doi:10.1002/ana.25809  
982